A screening assay based on host-pathogen interaction models identifies a set of novel antifungal benzimidazole derivatives

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4789-4801

  Burger Kentischer, Anke ^a   Finkelmeier, Doris ^a   Keller, Petra ^b   Bauer, Jörg ^c   Eickhoff, Holger ^c   Kleymann, Gerald ^d   Rayyan, Walid Abu ^d   Singh, Anurag ^d   Schröppel, Klaus ^d   Lemuth, Karin ^b   Wiesmüller, Karl Heinz ^c   Rupp, Steffen ^a  

^a FRAUNHOFER INSTITUTE FOR INTERFACIAL ENGINEERING AND BIOTECHNOLOGY IGB   (Germany)

^b UNIVERSITY OF STUTTGART   (Germany)

^c EMC MICROCOLLECTIONS GMBH   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (1 AMINOISOBUTYL) 1 (3 CHLOROBENZYL)BENZIMIDAZOLE; 2 (1 AMINOISOBUTYL) 1 (3 FLUOROBENZYL)BENZIMIDAZOLE; 2 (1 AMINOISOBUTYL) 1 (3 METHYLBENZYL)BENZIMIDAZOLE; ANTIFUNGAL AGENT; BENZIMIDAZOLE DERIVATIVE; ERGOSTEROL; FLUCONAZOLE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; GENETIC TRANSCRIPTION; HOST PATHOGEN INTERACTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PICHIA ANOMALA; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIFUNGAL AGENTS; BENZIMIDAZOLES; CANDIDA; CANDIDIASIS; CELL LINE; CHO CELLS; CRICETINAE; DRUG RESISTANCE, FUNGAL; ERGOSTEROL; GENOME, FUNGAL; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HOST-PATHOGEN INTERACTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC;

EID: 80052856427     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01657-10     Document Type: Article

References (46)

1. Angiolella, L., et al. 2002. Identification of major glucan-associated cell wall proteins of Candida albicans and their role in fluconazole resistance. Antimicrob. Agents Chemother. 46:1688-1694.
2. Barrett, T., et al. 2009. NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res. 37:D885-D890.
3. Bauer, J., et al. High-throughput screening-based identification and structure-activity relationship-characterization defined (S)-2-(1-aminoisobutyl) -1-(3-chlorobenzyl) benzimidazole as a highly antimycotic agent, non-toxic to cell lines. J. Med. Chem., in press.
4. Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57:289-300.
5. Brown, A. J., F. C. Odds, and N. A. Gow. 2007. Infection-related gene expression in Candida albicans. Curr. Opin. Microbiol. 10:307-313.
6. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M27-A3, vol. 28. CLSI, Wayne, PA.
7. Cornely, O. A., et al. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359.
8. Davidse, L. C. 1986. Benzimidazole fungicides: mechanism of action and biological impact. Annu. Rev. Phytopathol. 24:43-65.
9. Dieterich, C., et al. 2002. In vitro reconstructed human epithelia reveal contributions of Candida albicans EFG1 and CPH1 to adhesion and invasion. Microbiology 148:497-506.
10. Dudoit, S., J. Popper Schaffer, and J. C. Boldrick. 2003. Multiple hypothesis testing in microarray experiments. Stat. Sci. 28:71-103.
11. Edgar, R., M. Domrachev, and A. E. Lash. 2002. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30:207-210.
12. Elnima, E. I., M. U. Zubair, and A. A. Al-Badr. 1981. Antibacterial and antifungal activities of benzimidazole and benzoxazole derivatives. Antimicrob. Agents Chemother. 19:29-32.
13. EUCAST. 2008. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405.
14. Fonzi, W. A., and M. Y. Irwin. 1993. Isogenic strain construction and gene mapping in Candida albicans. Genetics 134:717-728. (Pubitemid 23193572)
15. Francois, I. E., A. M. Aerts, B. P. Cammue, and K. Thevissen. 2005. Currently used antimycotics: spectrum, mode of action and resistance occurrence. Curr. Drug Targets 6:895-907. (Pubitemid 41679177)
16. Guthrie, B. A., and W. Wickner. 1988. Yeast vacuoles fragment when microtubules are disrupted. J. Cell Biol. 107:115-120.
17. Hernandez, R., and S. Rupp. 2009. Human epithelial model systems for the study of Candida infections in vitro. Part II. Histologic methods for studying fungal invasion. Methods Mol. Biol. 470:105-123.
18. Hollomon, D. W., J. A. Butters, H. Barker, and L. Hall. 1998. Fungal beta-tubulin, expressed as a fusion protein, binds benzimidazole and phenylcarbamate fungicides. Antimicrob. Agents Chemother. 42:2171-2173.
19. Hope, W. W., E. M. Billaud, J. Lestner, and D. W. Denning. 2008. Therapeutic drug monitoring for triazoles. Curr. Opin. Infect. Dis. 21:580-586.
20. Jacobs, C. W., A. E. Adams, P. J. Szaniszlo, and J. R. Pringle. 1988. Functions of microtubules in the Saccharomyces cerevisiae cell cycle. J. Cell Biol. 107:1409-1426.
21. Kleymann, G., et al. 2002. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat. Med. 8:392-398.
22. Kleymann, G., and H. O. Werling. 2004. A generally applicable, highthroughput screening-compatible assay to identify, evaluate, and optimize antimicrobial agents for drug therapy. J. Biomol. Screen. 9:578-587.
23. Kojima, K., et al. 2004. Fungicide activity through activation of a fungal signalling pathway. Mol. Microbiol. 53:1785-1796.
24. Lönnstedt, I., and T. P. Speed. 2002. Replicated microarray data. Stat. Sin. 12:31-46.
25. Moosa, M. Y., J. D. Sobel, H. Elhalis, W. Du, and R. A. Akins. 2004. Fungicidal activity of fluconazole against Candida albicans in a synthetic vagina-simulative medium. Antimicrob. Agents Chemother. 48:161-167.
26. Mylonakis, E., A. Casadevall, and F. M. Ausubel. 2007. Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog. 3:e101.
27. Okoli, I., et al. 2009. Identification of antifungal compounds active against Candida albicans using an improved high-throughput Caenorhabditis elegans assay. PLoS One 4:e7025.
28. Pasqualotto, A. C., and D. W. Denning. 2008. New and emerging treatments for fungal infections. J. Antimicrob. Chemother. 61(Suppl. 1):i19-i30.
29. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
30. Pfaller, M. A., et al. 2005. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J. Clin. Microbiol. 43:5848-5859.
31. R Development Core Team. 2009, posting date. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
32. Rex, J. H., M. A. Pfaller, M. G. Rinaldi, A. Polak, and J. N. Galgiani. 1993. Antifungal susceptibility testing. Clin. Microbiol. Rev. 6:367-381.
33. Rex, J. H., et al. 2000. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin. Infect. Dis. 30:662-678.
34. Rios, J. L., M. C. Recio, and A. Villar. 1988. Screening methods for natural products with antimicrobial activity: a review of the literature. J. Ethnopharmacol. 23:127-149.
35. Ritchie, M. E., et al. 2007. A comparison of background correction methods for two-colour microarrays. Bioinformatics 23:2700-2707. (Pubitemid 350048334)
36. Rupp, S. 2007. Interactions of the fungal pathogen Candida albicans with the host. Future Microbiol. 2:141-151. (Pubitemid 46766988)
37. Rupp, S. 2008. Transcriptomics of the fungal pathogens focusing on Candida albicans human and animal relationships, p. 187-222. In A. Brakhage and P. Zipfel (ed.), The mycota, 2nd ed., vol. 7. Human and animal relationships. Springer-Verlag, Berlin, Germany.
38. Sanglard, D., and F. C. Odds. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2:73-85.
39. Sharma, D., et al. 2009. Synthesis, antimicrobial and antiviral activity of substituted benzimidazoles. J. Enzyme Inhib. Med. Chem. 24:1161-1168.
40. Silver, P. M., B. G. Oliver, and T. C. White. 2004. Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot. Cell 3:1391-1397.
41. Smyth, G. K. 2005. Limma: linear models for microarray data, p. 397-420. In R. Gentleman, V. Carrey, S. Dudoit, I. Irizzary, and W. Huber (ed.), Bioinformatics and computational biology solutions using R and bioconductor. Springer, New York, NY.
42. Smyth, G. K. 2004. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3:article 3.
43. Smyth, G. K., J. Michaud, and H. S. Scott. 2005. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21:2067-2075.
44. Smyth, G. K., and T. Speed. 2003. Normalization of cDNA microarray data. Methods 31:265-273.
45. Tortorano, A. M., et al. 2006. Candidaemia in Europe: epidemiology and resistance. Int. J. Antimicrob. Agents 27:359-366.
46. van Eldere, J., L. Joosten, V. Verhaeghe, and I. Surmont. 1996. Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test. J. Clin. Microbiol. 34:842-847.